Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 855 results for "ema"

Modernizing Medicine's Electronic Medical Records (EMR) System...

Modernizing Medicine, Inc. , the creator of the Electronic Medical Assistant ┬« (EMA), a cloud-based, specialty-specific electronic medical record (EMR) system, responded today to recent announcements from the Centers for ... Wall Street Business Network, 14 hours ago

182 images for ema

Newark Advertiser, 2 days ago
MedIndia, 2 days ago, 3 days ago
Malaysian Insider, 1 day ago
Dallas Hiram Patch, 1 day ago
Santa Barbara Independent, 1 day ago
Montreal Families, 1 day ago
Money Today, 5 days ago
Westerly Sun, 2 days ago
Westerly Sun, 2 days ago

Emera Inc. Completes Sale of Interest in Northeast Wind

Emera ( TSX:EMA ) announced today that the sale of its 49% interest in Northeast Wind Partners II, LLC (Northeast Wind) to First Wind Holdings, LLC (First Wind) has closed. The proposed sale was announced in November 2014. Northeast ...
 Town Hall10 hours ago EMERA : Completes Sale of Interest in Northeast Wind  4 Traders10 hours ago Press Release: Emera Inc. Completes Sale of Interest in Northeast Wind  iMarketReports10 hours ago

Amgen and Onyx submit sNDA and MAA for multiple myeloma drug to FDA and EMA

(MarketLine via COMTEX News Network) -- Amgen Inc., a biotechnology company, and its subsidiary Onyx Pharmaceuticals, Inc. have submitted a supplemental new drug application, or sNDA, to the FDA and a marketing authorization application, or MAA, to ...
 PredictWallStreet22 hours ago Amgen, Inc. Submits Applications For Cancer Drug Kyprolis┬« In US And Europe  Bidness Etc1 day ago

CELGENE : Garners Positive CHMP Opinion for Abraxane

Celgene International Sarl reported that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Abraxane (paclitaxel formulated as albumin-bound nanoparticles, or ...
 4 Traders22 hours ago EMA Updates Pediatric Investigation Plan Reexamination Procedure  FDA News1 day ago EMA committee issues positive opinion for Merck's Sivextro to treat ABSSSI  Pharmaceutical Business Review2 days ago EMA CHMP Adopts Positive Opinion for ABRAXANE-Carboplatin Combination for Treatment of NSCLC  Azonano2 days ago

News and press releases: Increasing the availability of veterinary medicines

27/01/2015 Increasing the availability of veterinary medicines EMA recommended 20 new medicines for animals in 2014 - three of which are for minor species and rare diseases In 2014, 20 new veterinary medicines were recommended for ...
 European Medicines Agency2 days ago Increasing the availability of veterinary medicines  FierceBiotech8 hours ago
Pharma Letter

Medicines update (24)

Generics approvals questioned The European Medicines Agency (EMA) is recommending suspending approval of a range of Indian generic medicines after allegations of a flawed testing and approval process. The medicines gained European Union ...
 Pharmacy News2 days ago EMA recommends sale suspension of medicines based on GVK Bio's flawed clinical data  Pharmaceutical Business Review3 days ago Suspend Dozens of Drugs Based on Flawed Studies, EMA Says  Dermatology Online Journal6 days ago GVK's trials doctored, stop drugs' sale: European body  Times of India6 days ago

EMA Accepts AZ Gout Drug

AstraZeneca's application for lesinurad, an unevenly successful gout treatment, has been accepted by the European Medicines Agency (EMA). AstraZeneca acquired lesinurad as part of the $1.3 billion purchase of Ardea Biosciences in 2013. The EMA's ...
 Nordic Life Science2 days ago EMA accepts marketing authorization application for lesinurad  Orthopedics Today3 days ago AstraZeneca receives MAA from EMA for hyperuricaemia drug  Individual.com6 days ago EMA accepts AstraZeneca MAA for gout med  Seeking Alpha1 week ago

The Medicines Company expects EMA's marketing authorisation for three hospital acute care products across three therapeutic categories

Medical solution company The Medicines Company (NasdaqGS:MDCO) said on Friday that it has been recommended for marketing authorisation for KENGREXAL, ORBACTIV , and RAPLIXA by the Committee for Medicinal Products for Human Use (CHMP) of the European ...
 BusinessWeek3 days ago

India's GVK Biosciences gets harsh accusations from EMA on fake generic trials

SINGAPORE--In no-holds-barred action, the European Medicines Agency has accused India-based CRO GVK Biosciences of systematically faking clinical trials for about 700 generic drugs marketed throughout the world. The products of dozens of generic ...
 FierceBiotech3 days ago German Regulator Hails EMA's Generic Drugs Suspension on GVK Bio Data  24Dunia2 days ago German regulator hails EMA's drugs suspension on GVK Bio data  Business Standard5 days ago EMA accepts need for regulators to improve communication of benefits of medicines  Manufacturing Chemist1 week ago

Hadasit Bio jumps on EMA orphan drug status

Enlivex Therapeutics is developing Apocell for treating graft-versus-host disease in bone marrow transplants. Hadasit Bio Holdings Ltd. (TASE: HDST ; Bulletin Board: HADSY ) portfolio company Enlivex Therapeutics Ltd.
 Globes1 week ago HADASIT BIO : jumps on EMA orphan drug status  4 Traders1 week ago Enlivex Therapeutics Ltd. Granted EU Orphan Drug Designation For Lead Product ApoCell For Graft-Versus-Host Disease 1/28/2015  ClinicSpace1 day ago Enlivex Granted EU Orphan Drug Designation for Lead Product ApoCell for Graft-Versus-Host Disease  FierceBiotech9 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less